Effectiveness of renin–angiotensin–aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis
Nephrology Dialysis Transplantation · 31.10.2023 · 38 (11) · 2485-2493
DOI: 10.1093/ndt/gfad105 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.05.2023. Verfasst von Mengyao Zeng und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Nephritis, Hereditary, Kidney Failure, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Department of Human Resources and Social Security of Jiangsu Province.
Abstract (Originalsprache)
Background
Although renin–angiotensin–aldosterone system (RAAS) blockers have been considered the primary treatment for patients with Alport syndrome (AS) for a decade, there is no comprehensive review with evidence-based analysis evaluating the effectiveness of RAAS blockers in AS.
Methods
A systematic review and meta-analysis was performed of published studies that compared outcomes related to disease progression between patients with AS receiving RAAS blockers with those taking non-RAAS treatment. Outcomes were meta-analyzed using the random effects models. Cochrane risk-of-bias, Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development and Evaluation methodology (GRADE) assessment determined the certainty of evidence.
Results
A total of eight studies (1182 patients) were included in the analysis. Overall, the risk of bias was low to moderate. Compared with non-RAAS treatment, RAAS blockers could reduce the rate of progression to end-stage kidney disease (ESKD) [four studies; hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.24–0.45; moderate certainty evidence]. After stratified by genetic types, a similar benefit was detected: male X-linked AS (XLAS) (HR 0.32, 95% CI 0.22–0.48), autosomal recessive AS (HR 0.25, 95% CI 0.10–0.62), female XLAS and autosomal dominant AS (HR 0.40, 95% CI 0.21–0.75). In addition, RAAS blockers showed a clear gradient of benefit depending on the stage of disease at the initiation of treatment.
Conclusion
This meta-analysis suggested that RAAS blockers could be considered as a specific therapy to delay of ESKD for AS with any genetic type, especially at the early stage of the disease, and every further more-effective therapy would be advised to be applied on top of this standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
ORCID-Profile: Zhihong Liu
Förderung
- Department of Human Resources and Social Security of Jiangsu Province
Zitieren
APA
Zeng, M., Di, H., Liang, J., & Liu, Z. (2023). Effectiveness of renin–angiotensin–aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 38(11), 2485-2493. https://doi.org/10.1093/ndt/gfad105
Vancouver
Zeng M, Di H, Liang J, Liu Z. Effectiveness of renin–angiotensin–aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2023;38(11):2485-2493. doi:10.1093/ndt/gfad105
BibTeX
@article{Zeng2023,
author = {Zeng, Mengyao and Di, Hongling and Liang, Ju and Liu, Zhihong},
title = {Effectiveness of renin–angiotensin–aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {11},
pages = {2485--2493},
doi = {10.1093/ndt/gfad105}
}
EUVIMED